Search research articles
Contact Us
Filters
Showing results (71-80 of 219) with videos related to
Page
of 22
Sort By:
Journal of the American Academy of Dermatology
|
July 17, 2017
Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)
Andrew Blauvelt, Kim A Papp, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology
|
January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial
Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
Journal of Drugs in Dermatology : JDD
|
August 21, 2018
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years
Christopher E M Griffiths, Kim A Papp, Alexa B Kimball, et al.
Journal of the American Academy of Dermatology
|
April 3, 2018
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
Kim A Papp, Joseph F Merola, Alice B Gottlieb, et al.
American Journal of Clinical Dermatology
|
May 27, 2026
Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study
Joel C Joyce, H Chih-Ho Hong, Dareen D Siri, et al.
Dermatology and Therapy
|
August 23, 2024
Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis
April W Armstrong, Peter Foley, Yan Liu, et al.
Journal of Cutaneous Medicine and Surgery
|
March 24, 2022
Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab
Wayne Gulliver, Afsaneh Alavi, Marni C Wiseman, et al.
The Journal of Investigative Dermatology
|
January 23, 2025
Phase II Randomized Trial of BI 730357, an Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis
Melinda J Gooderham, Ulrich Mrowietz, Werner Kadus, et al.
Journal of the American Academy of Dermatology
|
March 19, 2011
Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study
Bruce E Strober, Yves Poulin, Francisco A Kerdel, et al.
The Journal of Dermatological Treatment
|
May 26, 2024
Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)
Andreas Pinter, Kilian Eyerich, Antonio Costanzo, et al.
Page
of 22
Search research articles
Search
Showing results (71-80 of 219) with videos related to
Sort By:
Page
of 22
Journal of the American Academy of Dermatology
|
July 17, 2017
Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)
Andrew Blauvelt, Kim A Papp, Mark G Lebwohl, et al.
Journal of the American Academy of Dermatology
|
January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial
Andrew Blauvelt, Kim A Papp, Christopher E M Griffiths, et al.
Journal of Drugs in Dermatology : JDD
|
August 21, 2018
Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years
Christopher E M Griffiths, Kim A Papp, Alexa B Kimball, et al.
Journal of the American Academy of Dermatology
|
April 3, 2018
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
Kim A Papp, Joseph F Merola, Alice B Gottlieb, et al.
American Journal of Clinical Dermatology
|
May 27, 2026
Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study
Joel C Joyce, H Chih-Ho Hong, Dareen D Siri, et al.
Dermatology and Therapy
|
August 23, 2024
Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis
April W Armstrong, Peter Foley, Yan Liu, et al.
Journal of Cutaneous Medicine and Surgery
|
March 24, 2022
Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab
Wayne Gulliver, Afsaneh Alavi, Marni C Wiseman, et al.
The Journal of Investigative Dermatology
|
January 23, 2025
Phase II Randomized Trial of BI 730357, an Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis
Melinda J Gooderham, Ulrich Mrowietz, Werner Kadus, et al.
Journal of the American Academy of Dermatology
|
March 19, 2011
Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study
Bruce E Strober, Yves Poulin, Francisco A Kerdel, et al.
The Journal of Dermatological Treatment
|
May 26, 2024
Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)
Andreas Pinter, Kilian Eyerich, Antonio Costanzo, et al.
Page
of 22